Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

Bolla, M.; Collette, Laurence; Blank, L.E.C.M.; Warde, Padraig; Dubois, J.B.; Mirimanoff, René-Olivier; Storme, Guy; Bernier, Jacques; Kuten, Abraham; Sternberg, Cora N.; Mattelaer, J; Torecilla, José Lopez; Pfeffer, J Rafael; Cutajar, C. L.; Zurlo, Alfredo; Piérart, M.

doi:10.1016/s0140-6736(02)09408-4

Cited by 1,586 publications

(744 citation statements)

References 18 publications

Supporting

Mentioning

697

Contrasting

Unclassified

Order By: Relevance

“…In patients with locally advanced disease (T3 -4) the rates of local control with radiation therapy alone have been reported to range from 60 to 77% (Shipley et al, 1995). In a recent Phase III trial in men with locally advanced prostate cancer, the rate of local regional control in the radiation-alone arm was 83% (Bolla et al, 2002). Since this trial did not require prostate biopsies following treatment, the rate of loco-regional control is likely an overestimate.…”

mentioning

confidence: 88%

1α,25-Dihydroxyvitamin D3 (calcitriol) and its analogue, 19-nor-1α,25(OH)2D2, potentiate the effects of ionising radiation on human prostate cancer cells

et al. 2003

View full text Add to dashboard Cite

Radiotherapy with external beam radiation or brachytherapy is an established therapeutic modality for prostate cancer. Approximately 30% of patients with localised prostate cancer relapse at the irradiated site. Secondary effects of ionising radiation (IR), for example, bowel and bladder complications, are common. Thus, the search for biological response modifiers that could potentiate the therapeutic effects of radiation and limit the occurrence of serious side effects is an important task in prostate cancer therapy.

show abstract

mentioning

confidence: 88%

1α,25-Dihydroxyvitamin D3 (calcitriol) and its analogue, 19-nor-1α,25(OH)2D2, potentiate the effects of ionising radiation on human prostate cancer cells

et al. 2003

View full text Add to dashboard Cite

show abstract

“…1 It is well established that the use of androgen deprivation therapy (ADT) concurrently with radiation, improves overall survival in patients with locally advanced disease compared with patients who received radiation alone. 2,3,4 Potential reasons for this include, but are not restricted to, the anti-angiogenic 5 and pro-apoptotic 6 effects of ADT, as well as to cyto-reduction and control of micrometastatic disease. 7 We have recently suggested another potential mechanism for the radiosensitizing effect of ADT, namely that ADT enhances the vulnerability of PC cells to toxic oxidative stress induced by radiation.…”

Section: Introductionmentioning

confidence: 99%

Androgens induce oxidative stress and radiation resistance in prostate cancer cells though NADPH oxidase

Monardo

Bryskin

et al. 2009

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) facilitates the response of prostate cancer (PC) to radiation. Androgens have been shown to induce elevated basal levels of reactive oxygen species (ROS) in PC, leading to adaptation to radiation-induced cytotoxic oxidative stress. Here, we show that androgens increase the expression of p22 phox and gp91 phox subunits of NADPH oxidase (NOX) and ROS production by NOX2 and NOX4 in PC. Pre-radiation treatment of 22Rv1 human PC cells with NOX inhibitors sensitize the cells to radiation similarly to ADT, suggesting that their future usage may spare the need for adjuvant ADT in PC patients undergoing radiation.

show abstract

“…The EORTC 22863 trial evaluated the effectiveness of adjuvant therapy with 3.6 mg goserelin initiated at the onset of radiotherapy and continued for 3 years in patients with high-risk nonmetastatic prostate cancer [28]. A total of 415 patients were randomized to receive either radiotherapy with immediate hormone treatment or radiotherapy alone with hormonal treatment for disease progression.…”

Section: Radiotherapy In Combination With Hormone Treatmentmentioning

confidence: 99%

“…Timing has varied among different trials. Goserelin was added during the final week of RTOG 85-31 [29]and during the first week of EORTC 22863 [28]. There were also differences in the duration of adjuvant goserelin therapy in these studies.…”

Section: Radiotherapy In Combination With Hormone Treatmentmentioning

confidence: 99%

Management of locally advanced prostate cancer

Payne¹

2008

Asian J Androl

View full text Add to dashboard Cite

The management of all stages of prostate cancer is an increasingly complex process and involves a variety of available treatments and many disciplines. Despite prostate-specific antigen (PSA) testing, the presentation of prostate cancer at a locally advanced stage is common in the UK, accounting for one-third of all new cases. There is no universally accepted definition of locally advanced prostate cancer; the term is loosely used to encompass a spectrum of disease profiles that show high-risk features. Men with high-risk prostate cancer generally have a significant risk of disease progression and cancer-related death if left untreated. High-risk patients, including those with locally advanced disease, present two specific challenges. There is a need for local control as well as a need to treat any microscopic metastases likely to be present but undetectable until disease progression. The optimal treatment approach will therefore often necessitate multiple modalities. The exact combinations, timing and intensity of treatment continue to be strongly debated. Management decisions should be made after all treatments have been discussed by a multidisciplinary team (including urologists, oncologists, radiologists, pathologists and nurse specialists) and after the balance of benefits and side effects of each therapy modality has been considered by the patient with regard to his own individual circumstances. This article reviews the current therapy options.

show abstract

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

Cited by 1,586 publications

References 18 publications

1α,25-Dihydroxyvitamin D3 (calcitriol) and its analogue, 19-nor-1α,25(OH)2D2, potentiate the effects of ionising radiation on human prostate cancer cells

1α,25-Dihydroxyvitamin D3 (calcitriol) and its analogue, 19-nor-1α,25(OH)2D2, potentiate the effects of ionising radiation on human prostate cancer cells

Androgens induce oxidative stress and radiation resistance in prostate cancer cells though NADPH oxidase

Management of locally advanced prostate cancer

Contact Info

Product

Resources

About